Trader’s Watch List: Fifth Third Bancorp (NASDAQ:FITB), Gilead Sciences, Inc. (NASDAQ:GILD)

On Thursday, Shares of Fifth Third Bancorp (NASDAQ:FITB), added 3.44% and closed at $23.74 in the last trading session. The last trading range of the stock ranges between $23.09 and $23.93. The company’s Market capitalization is $19.01 Billion with the total Outstanding Shares of 755.61 million. Fifth Third Bancorp (FITB) declared recently that Aravind Immaneni will be joining the Bank effective Nov. 14, 2016, as executive vice president and chief operations and technology officer. Immaneni will report to President and CEO Greg D. Carmichael. He will be responsible for all aspects of information technology and back-office operations at the $143 billion bank.

Immaneni has extensive experience in transforming businesses by reinventing operations, technology and processes. He joins Fifth Third from TD Bank, where he presently is head of Retail Distribution Strategy & Operations. In that role, Immaneni has oversight for branch operations, infrastructure, distribution strategy and transformation for TD Bank’s 1,280-branch network from Maine to Florida. Before his current role, he served as head of Retail Bank Operations, with oversight for back-office operations, systems, loan origination and underwriting for TD’s Consumer Bank.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $13.84 and reached to max level of $23.93. The EPS of company is strolling at 2.24.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD), dropped -0.80% and closed at $77.84 in the last trading session. The last trading range of the stock ranges between $76.94 and $80.00. The company’s Market capitalization is $108.69 Billion with the total Outstanding Shares of 1.32 billion. Gilead Sciences, Inc. (GILD) recently declared that the U.S. Food and Drug Administration (FDA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

Vemlidy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. See below for important safety information.

Vemlidy is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300mg. Data show that because Vemlidy has greater plasma stability and more efficiently delivers tenofovir to hepatocytes contrast to Viread, it can be given at a lower dose, resulting in less tenofovir in the bloodstream. As a result, Vemlidy improved renal and bone laboratory safety parameters contrast to Viread.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $71.39 and reached to max level of $109.23. The EPS of company is strolling at 10.78.

Leave a Reply

Your email address will not be published. Required fields are marked *